BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
BioMarin (NASDAQ: BMRN) will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Wednesday, August 12, 2026, at 8:00AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin (NASDAQ: BMRN) will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Wednesday, August 12, 2026, at 8:00AM ET. A live audio webcast and a time-limited archived replay will be accessible via the company’s investor website.
Details
News Market Reaction – BMRN
On Aug 10, the day this news came out, BMRN closed 7.95% above the previous close. Argus tracked a peak move of +6.6% during that session. Our momentum scanner recorded 86 alerts for this stock that day. Relative volume reached 2.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Aug 10 session.
Key Figures
- Conference edition
- 46th annual
- Canaccord Genuity Growth Conference
- Presentation date and time
- August 12, 2026 at 8:00 AM ET
- Management presentation
- Company founding year
- 1997
- BioMarin company history
- Commercial therapies
- nine commercial therapies
- Company description
Historical Context
-
Announced second-quarter results conference call and webcast scheduled for August 6
-
Entered early research collaboration and exclusive license for ReNU syndrome medicine
-
FDA accepted VOXZOGO supplemental application and set February 28, 2027 action date
-
Reported three-year VOXZOGO data and early BMN 333 Phase 1 results
-
Reported positive CANOPY-HCH-3 results with significant growth-velocity improvement
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-at-the-canaccord-genuity-46th-annual-growth-conference-on-wednesday-august-12-2026-at-800am-et-in-boston-302844104.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.